<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">In 2011, the multi-drug regimen FOLFIRINOX, consisting of 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin, was superior to gemcitabine in patients with metastatic pancreatic cancer (median OS 11.1 vs. 6.8 months, 
 <italic>p</italic> &lt; 0.001) [
 <xref ref-type="bibr" rid="CR13">13</xref>]. For locally advanced pancreatic cancer (LAPC), no RCT has been conducted, yet a favorable median OS with FOLFIRINOX of 24 months was found in a patient-level meta-analysis including 315 patients [
 <xref ref-type="bibr" rid="CR14">14</xref>]. In comparison, the median OS with gemcitabine for LAPC ranged from 8 to 13 months in previous studies [
 <xref ref-type="bibr" rid="CR15">15</xref>]. In the neoadjuvant setting, a patient-level meta-analysis of FOLFIRINOX for borderline resectable pancreatic cancer found a median OS of 22.2 months [
 <xref ref-type="bibr" rid="CR16">16</xref>]. In recent years, FOLFIRINOX has become the most commonly used neoadjuvant chemotherapy in observational studies and ongoing phase II trials [
 <xref ref-type="bibr" rid="CR17">17</xref>].
</p>
